What they were paid
BridgeBio Pharma Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $50,000 | $274,959 | $274,988 | — | $599,947 |
| FY2024 | $50,000 | $0 | $549,998 | $0 | $599,998 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BridgeBio Pharma, Inc. DEF 14A filed April 24, 2026, accession 0001140361-26-016723, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themAudit (Chair)
The rest of the BridgeBio Pharma board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Ali J. Satvat | Independent Director | $599,947 |
| Andrew W. Lo, Ph.D | Independent Director | $649,947 |
| Charles Homcy, M.D | Director | $1,124,114 |
| Douglas A. Dachille | Independent Director | $599,947 |
| Eric Aguiar, M.D | Independent Director | $599,947 |
| Frank P. McCormick, Ph.D., F.R.S., D.Sc | Director | $1,099,947 |
| Fred Hassan | Lead Independent Director | $599,947 |
| Hannah A. Valantine, M.D | Independent Director | $599,947 |
| James C. Momtazee | Independent Director | $599,947 |
| Jennifer E. Cook | Independent Director | $599,947 |
| Neil Kumar, Ph.D | Director | $0 |
| Randal W. Scott, Ph.D | Independent Director | $599,947 |
| Ronald J. Daniels | Independent Director | $599,947 |
The full BridgeBio Pharma compensation record
free company briefThis page is one director within BridgeBio Pharma's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat